Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
Date:5/31/2011

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.  Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Goldman Sachs conference.  Mark Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recordings will be made available on the website following the events. To access the live webcasts, please log on to Amylin's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin to Advance Key Value-Driving Opportunities in 2011
2. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
3. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
7. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A ... 2015 - 2022," projects that the global biometric technology market is expected to generate ... to 2022. Continue Reading ... ...      (Logo: ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES┬« 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
Breaking Biology News(10 mins):